Dose-escalation of Cellistem-OA in Patients With Knee Osteoarthritis

Phase 1 Unknown 24 enrolled Universidad de los Andes, Chile

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A phase I dose-escalation trial to assess safety and efficacy of allogeneic MSC based-treatment (cellistem-OA) in patients with symptomatic knee osteoarthritis

Timeline

Start: 2019-03-01
Primary completion: 2019-10-30
Completion: 2019-12-30

Publications

Matas J, Garcia C, Poblete D, Vernal R, Ortloff A, Luque-Campos N, Hidalgo Y, Cuenca J, Infante C, Cadiz MI, Khoury M, Luz-Crawford P, Espinoza F. A Phase I Dose-Escalation Clinical Trial to Assess the Safety and Efficacy of Umbilical Cord-Derived Mesenchymal Stromal Cells in Knee Osteoarthritis. Stem Cells Transl Med. 2024 Mar 15;13(3):193-203. doi: 10.1093/stcltm/szad088.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mesenchymal stem cells	Cell therapy	2e+06 cells	Other
Subject	mesenchymal stem cells	Cell therapy	2e+07 cells	Other
Subject	mesenchymal stem cells	Cell therapy	8e+07 cells	Other

Dose-escalation of Cellistem-OA in Patients With Knee Osteoarthritis

Summary

Timeline

Publications

Drugs

Indications